Effect of Rifapentine and Rifampicin on Anti-Tuberculosis  

作　　者：Weijia Lin Yaping Zhang Zhi Liu Ping Feng Zhihua Zhang Xiulong Zhang Weijia Lin;Yaping Zhang;Zhi Liu;Ping Feng;Zhihua Zhang;Xiulong Zhang(Department of Respiratory Medicine, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China;Department of Orthopedic Surgery, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China)

机构地区：[1]Department of Respiratory Medicine, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China [2]Department of Orthopedic Surgery, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China

出　　处：《Journal of Tuberculosis Research》2021年第3期205-210,共6页结核病研究（英文）

摘　　要：<b><span style="font-family:Verdana;">Objective:</span></b><span style="font-family:Verdana;"> To investigate the clinical effect of rifapentine and rifampicin in the treatment of pulmonary tuberculosis.</span><b> </b><span style="font-family:Verdana;"><b></b></span><b><b><span style="font-family:Verdana;">Methods:</span></b><span style="font-family:Verdana;"></span></b><b> </b><span style="font-family:Verdana;">Seventy-two cases of patients with initial treatment of pulmonary tuberculosis who attended the First Hos</span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">pital Affiliated to Hebei North </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">University</span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;"> from February 2017 to August 2019 we</span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">re </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">selected. They were randomly divided into observation group and control gro</span></span></span><span><span><span style="font-family:;" "=""><span style="font-family:Verdana;">up, with 36 cases in each group. The observation group was treated with isoniazid + rifapentine + ethambutol, while the control group was treated with isoniazid + rifampicin + ethambutol. The symptom relief, image absorption and adverse reactions were compared between the two groups. <b></b></span><b><b><span style="font-family:Verdana;">Results:</span></b><span style="font-family:Verdana;"></span></b><span style="font-family:Verdana;"> The rate of symp</span></span></span></span><span><span><span style="font-family:;" "=""><span style="font-family:Verdana;">tom relief was 86.11% in the observation group and 94.44% in the control</span><span><sp<b><span style="font-family:Verdana;">Objective:</span></b><span style="font-family:Verdana;"> To investigate the clinical effect of rifapentine and rifampicin in the treatment of pulmonary tuberculosis.</span><b> </b><span style="font-family:Verdana;"><b></b></span><b><b><span style="font-family:Verdana;">Methods:</span></b><span style="font-family:Verdana;"></span></b><b> </b><span style="font-family:Verdana;">Seventy-two cases of patients with initial treatment of pulmonary tuberculosis who attended the First Hos</span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">pital Affiliated to Hebei North </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">University</span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;"> from February 2017 to August 2019 we</span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">re </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">selected. They were randomly divided into observation group and control gro</span></span></span><span><span><span style="font-family:;" "=""><span style="font-family:Verdana;">up, with 36 cases in each group. The observation group was treated with isoniazid + rifapentine + ethambutol, while the control group was treated with isoniazid + rifampicin + ethambutol. The symptom relief, image absorption and adverse reactions were compared between the two groups. <b></b></span><b><b><span style="font-family:Verdana;">Results:</span></b><span style="font-family:Verdana;"></span></b><span style="font-family:Verdana;"> The rate of symp</span></span></span></span><span><span><span style="font-family:;" "=""><span style="font-family:Verdana;">tom relief was 86.11% in the observation group and 94.44% in the control</span><span><sp

关 键 词：RIFAMPICIN RIFAPENTINE Pulmonary Tuberculosis 

分 类 号：O17[理学—数学]